CytoReason

The latest Q3 Israeli Tech Review by IVC Data and Insights and LeumiTech highlights the resilience and growth of Israel's high-tech sector, even in a challenging geopolitical landscape. Israeli hi-tech raised a total of $7.4 billion in 330 deals from Q1 to Q3 2024, surpassing 2023's total. No surprise here: generative AI is drawing major investment and driving innovation in the life sciences. We’re proud at CytoReason to be listed here as a top investment in Q3, and to be part of this thriving ecosystem. Read the full report here: https://lnkd.in/eP8NHFpg

At CytoSummit this year we focused on bridging the gaps: •⁠ ⁠Between molecular and clinical data. •⁠ ⁠⁠Between data and insight. •⁠ ⁠⁠And between researchers and decision-makers.  All in the name of improving probability of success for our customers in phase 2 clinical trials. More about CytoReason’s science and technology in the link below 👇

We’re honored to be ranked top 5 in Power in Diversity's 2023 Diversity Report! We also look forward to a future where we no longer need a special award to recognize the evident truth – one that we’ve always held at CytoReason – that talent knows no age, gender, race or religion. Thank you Power in Diversity for this recognition!

Our focus here at CytoReason is on improving probability of success in phase 2 clinical trials. This matters not just to pharma companies, but also to patients suffering from a range of debilitating illnesses. Success in phase 2 trials can help us identify treatments with fewer side effects, better quality of life outcomes, and improved disease control compared to Standard of Care drugs. Thanks Parker Moss from Exscientia for driving home this point at our recent CytoSummit, and for reminding us why our work matters.

I just returned from CytoSummit in Crete. Together with the CytoReason team and an impressive group of industry experts, we focused on one question: "How can we empower our customers to improve the probability of success in phase 2 clinical trials?" Low efficacy remains one of the biggest challenges in drug development today. 90% of drug candidates fail in clinical trials, resulting in hundreds of millions of dollars and years of research being lost. At CytoReason, we use our proprietary disease models to tackle this challenge. We help our customers identify the right indications and the most responsive patients—before trials even begin. While outcomes can never be fully assured, our goal is to provide data-driven insights that give scientists and pharma executives the confidence to make informed decisions and maximize their chances of success. Learn more about our disease models via the link in the comment below 👇

Fascinating episode of Tech on Drugs is up today with AION Labs CTO Yair Benita. Among the highlights: •⁠ ⁠What major shift did Keytruda's development introduce to the industry? •⁠ ⁠How did pharma's 'Kodak moment’ come about? •⁠ ⁠What needs to happen in pharma R&D so data is no longer JUST supporting decisions, but actually driving them? Yair is an accomplished computational biologist who spent more than 20 years studying biology through omics and clinical data in an effort to piece together mechanisms of human disease. He’s been leading computational teams in drug discovery at CytoReason, Compugen, and Merck. In this candid conversation, Yair reflects with me on the highs and the lows of the past two decades - in his professional journey, and in the industry at large. Link to full episode in comment below 👇

שנה קשוחה עברה על כולנו, גם על מנהלות HR. אבל כדברי צ׳רצ׳יל: "לעולם אל תיתן למשבר טוב להתבזבז". מאמר מלא תובנות בהשתתפות VP HR של סייטוריזן - Michal Katzir. למאמר המלא: https://lnkd.in/ejS8THhy

It’s been a tough year in Israel and in the world.   Our work at CytoReason keeps us sane (mostly), our connections keep us happy, our mission - to improve probability of success in clinical trials – brings us meaning.   Wishing a Happy Rosh Hashanah to all those celebrating! 🍯🍎 שנה טובה🍷🍏

At CytoSummit, on the beautiful island of Crete, we gathered CytoReason’s employees to tackle one of the biggest challenges facing drug developers today: improving the probability of success in Phase 2 clinical trials. With an incredible lineup of guest speakers, we explored the latest advances in generative AI for drug development and reflected on CytoReason’s differentiated position in the digital health market. David Ruau - NVIDIA, Marie Lübkert - Nomura, Dr Leonid Shapiro - Candesic, Yair Benita - AION Labs, Parker Moss - Exscientia

We just came back from CytoSummit, our annual employee conference, held on the beautiful island of Crete. CytoSummit is first and foremost about honoring our people. It’s been a challenging year, and without the passion, hard work, and great minds of our amazing Cytos, there's no way we would have powered through. We faced some tough questions throughout our stay. Souvlaki or Gyros? Ouzo or Tsipouro? Beach strolls or mountain hikes? But in all seriousness, we focused on the question we’ve asked from day one at CytoReason: "How can we improve the probability of success in phase 2 clinical trials?" We believe that tackling this challenge with our differentiated computational models will not only help our customers make medicine more predictable, but more importantly, improve the lives of people battling some of the most debilitating diseases out there. A big thank you to our guests, including Parker Moss from Exscientia, David Ruau from NVIDIA, Yair Benita from AION Labs, Dr Leonid Shapiro from Candesic, and Marie Lübkert from Nomura. Your insights helped us zoom out beyond our day-to-day work, and remember that we’re at the forefront of pharma AI. We came back feeling proud. Stay tuned for more takeaways from CytoSummit in the coming weeks!